Morgan Morgan, PA
Physician Assistant · Shelby, NCNPI 1548821291
Payments from drug & device makers
Across 1,119 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$3K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Alkermes, Inc.$1K
- plus $8K from 25 others
What the payments were for
- Food & beverage$17,65198%
- Education$3212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 171 | $2,585 |
| AbbVie | 210 | $2,344 |
| Teva Pharmaceuticals USA, Inc. | 56 | $1,324 |
| Otsuka America Pharmaceutical, Inc. | 89 | $1,262 |
| Johnson & Johnson | 52 | $1,237 |
| Alkermes, Inc. | 55 | $1,163 |
| Vanda Pharmaceuticals Inc. | 47 | $929 |
| Lundbeck LLC | 60 | $829 |
| Supernus Pharmaceuticals, Inc. | 41 | $790 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $665 |
| Almatica Pharma LLC | 60 | $624 |
| Axsome Therapeutics, Inc. | 29 | $546 |
| Indivior Inc. | 26 | $504 |
| Bausch Health US, LLC | 26 | $493 |
| E.r. Squibb & Sons, L.L.C. | 19 | $404 |
| Corium, LLC | 39 | $396 |
| Tris Pharma Inc | 17 | $301 |
| Idorsia Pharmaceuticals US Inc | 16 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $192 |
| Merck | 10 | $187 |
| Collegium Pharmaceutical, Inc. | 15 | $183 |
| Ironshore Pharmaceuticals Inc. | 7 | $156 |
| USWM, LLC | 7 | $129 |
| Sunovion Pharmaceuticals Inc. | 8 | $113 |
| Jazz Pharmaceuticals Inc. | 5 | $108 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $107 |
| Eisai Inc. | 3 | $50 |
| Braeburn Inc. | 2 | $36 |
| Bristol Myers Squibb | 1 | $32 |
| Noven Therapeutics, LLC | 2 | $31 |
| Hikma Pharmaceuticals USA | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,972 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 34 | $323,432 |
| IngrezzaValbenazine Tosylate | 27 | $228,319 |
| VraylarCariprazine Hcl | 130 | $204,125 |
| RexultiBrexpiprazole | 111 | $203,141 |
| TrintellixVortioxetine Hydrobromide | 145 | $126,512 |
| Invega TrinzaPaliperidone Palmitate | 12 | $125,448 |
| FanaptIloperidone | 37 | $111,149 |
| SpravatoEsketamine Hcl | 72 | $92,471 |
| Abilify AsimtufiiAripiprazole | 11 | $63,437 |
| AuvelityDextromethorphan Hbr/Bupropion | 49 | $63,131 |
| UzedyRisperidone | 12 | $50,308 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $44,211 |
| BelsomraSuvorexant | 93 | $39,321 |
| QuviviqDaridorexant Hcl | 65 | $34,063 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $6,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $1,324 | $373,74146 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii | $1,262 | $266,578122 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,585 | $228,31927 claims |
| Johnson & JohnsonInvega Trinza, Spravato | $1,237 | $217,91984 claims |
| AbbVieVraylar | $2,344 | $204,125130 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $192 | $132,723160 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $929 | $111,14937 claims |
| Axsome Therapeutics, Inc.Auvelity | $546 | $63,13149 claims |
| Alkermes, Inc.Lybalvi | $1,163 | $44,21126 claims |
| MerckBelsomra | $187 | $39,32193 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $235 | $34,06365 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $17 | $5,90541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Shelby
- Taylor SzucsShelby$22K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.